SEARCH

SEARCH BY CITATION

References

  • 1
    Khot UN, Khot MB, Bajzer CT et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA2003; 290: 898904.
  • 2
    Erren M, Reinecke H, Junker R et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol1999; 19: 235563.
  • 3
    Melander O, Newton-Cheh C, Almgren P et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA2009; 302: 4957.
  • 4
    Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab2004; 89: 151225.
  • 5
    Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet1993; 341: 5158.
  • 6
    Dandona P, Nix D, Wilson MF et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab1994; 79: 16058.
  • 7
    Linscheid P, Seboek D, Nylen ES et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology2003; 144: 557884.
  • 8
    Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Muller B. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med2004; 32: 171521.
  • 9
    Abbasi A, Corpeleijn E, Postmus D et al. Plasma procalcitonin is associated with obesity, insulin resistance, and the metabolic syndrome. J Clin Endocrinol Metab2010; 95: E2631.
  • 10
    Kafkas N, Venetsanou K, Patsilinakos S et al. Procalcitonin in acute myocardial infarction. Acute Card Care2008; 10: 306.
  • 11
    Ataoglu HE, Yilmaz F, Uzunhasan I et al. Procalcitonin: a novel cardiac marker with prognostic value in acute coronary syndrome. J Int Med Res2010; 38: 5261.
  • 12
    Kelly D, Khan SQ, Dhillon O et al. Procalcitonin as a prognostic marker in patients with acute myocardial infarction. Biomarkers2010; 15: 32531.
  • 13
    Sinning CR, Sinning JM, Schulz A et al. Association of serum procalcitonin with cardiovascular prognosis in coronary artery disease. Circ J2011; 75: 118491.
  • 14
    Morgenthaler NG, Struck J, Fischer-Schulz C, Bergmann A. Sensitive immunoluminometric assay for the detection of procalcitonin. Clin Chem2002; 48: 78890.
  • 15
    Morgenthaler NG, Struck J, Fischer-Schulz C, Seidel-Mueller E, Beier W, Bergmann A. Detection of procalcitonin (PCT) in healthy controls and patients with local infection by a sensitive ILMA. Clin Lab2002; 48: 26370.
  • 16
    Rosvall M, Janzon L, Berglund G, Engstrom G, Hedblad B. Incident coronary events and case fatality in relation to common carotid intima-media thickness. J Intern Med2005; 257: 4307.
  • 17
    Rosvall M, Janzon L, Berglund G, Engstrom G, Hedblad B. Incidence of stroke is related to carotid IMT even in the absence of plaque. Atherosclerosis2005; 179: 32531.
  • 18
    Engstrom G, Jerntorp I, Pessah-Rasmussen H, Hedblad B, Berglund G, Janzon L. Geographic distribution of stroke incidence within an urban population: relations to socioeconomic circumstances and prevalence of cardiovascular risk factors. Stroke2001; 32: 1098103.
  • 19
    Hammar N, Alfredsson L, Rosen M, Spetz CL, Kahan T, Ysberg AS. A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden. Int J Epidemiol2001; 30(Suppl 1): S304.
  • 20
    Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol2006; 47: C1931.
  • 21
    Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation2004; 109: 19559.
  • 22
    Meisner M, Lohs T, Huettemann E, Schmidt J, Hueller M, Reinhart K. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol2001; 18: 7987.
  • 23
    Saemann MD, Poglitsch M, Kopecky C, Haidinger M, Horl WH, Weichhart T. The versatility of HDL: a crucial anti-inflammatory regulator. Eur J Clin Invest2010; 40: 113143.
  • 24
    Engstrom G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgarde F. Long-term effects of inflammation-sensitive plasma proteins and systolic blood pressure on incidence of stroke. Stroke2002; 33: 27449.
  • 25
    Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun2010; 34: J25865.
  • 26
    Miyakis S, Georgakopoulos P, Kiagia M et al. Serial serum procalcitonin changes in the prognosis of acute stroke. Clin Chim Acta2004; 350: 2379.
  • 27
    Di Napoli M, Schwaninger M, Cappelli R et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke2005; 36: 131629.
  • 28
    Zia E, Hedblad B, Pessah-Rasmussen H, Berglund G, Janzon L, Engstrom G. Blood pressure in relation to the incidence of cerebral infarction and intracerebral hemorrhage. Hypertensive hemorrhage: debated nomenclature is still relevant. Stroke2007; 38: 26815.
  • 29
    Saremi A, Anderson RJ, Luo P et al. Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis2009; 203: 6104.